WHIPPANY, N.J., SEPTEMBER 1, 2024 – Detailed results from the Phase III FINEARTS-HF trial presented today at the European Society of Cardiology (ESC) Congress 2024 during a late-breaking Hot Line session and simultaneously published in the New England Journal of Medicine showed that KERENDIA® (finerenone) achieved a statistically significant reduction of the composite of cardiovascular death and total (first and recurrent) heart failure (HF) events, defined as either an unplanned hospitalization for HF or an urgent HF visit, by 16% (rate ratio, 0.84; 95% confidence interval [CI], 0.74 to 0.95; P = 0.007) in patients with HF and a LVEF ≥40% (left ventricular ejection fraction) compared to placebo in addition to a patients’ prescribed treatment regimen.1
KERENDIA is the first-and-only non-steroidal mineralocorticoid receptor antagonist (MRA) to meet a primary composite cardiovascular endpoint in a Phase III trial investigating patients with HF and LVEF ≥40%.1
KERENDIA is currently approved to reduce the risk of cardiovascular death, hospitalization for HF, non-fatal myocardial infarction (MI), sustained eGFR decline, and end-stage kidney disease in adult patients with chronic kidney disease (CKD) associated with type 2 diabetes (T2D).2
KERENDIA already has established cardiovascular benefit (reduction in hospitalization for HF, CV death and non-fatal MI) in adults with CKD associated with T2D,2 and this new data provides positive results in a different patient population not limited to CKD in T2D – patients diagnosed with HF (LVEF ≥40).1